Arrowhead Pharmaceuticals Inc (ARWR)
19.69
+0.19
(+0.97%)
USD |
NASDAQ |
Jan 07, 14:40
Arrowhead Pharmaceuticals SG&A Expense (Quarterly): 25.79M for Sept. 30, 2024
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Sarepta Therapeutics Inc | 128.20M |
| Amgen Inc | 1.625B |
| Vertex Pharmaceuticals Inc | 371.80M |
| Avidity Biosciences Inc | 23.27M |
| Harmony Biosciences Holdings Inc | 56.16M |